Premium
Serum oncostatin M in multiple myeloma: association with prognostic factors
Author(s) -
KOSKELA KARI,
PELLINIEMI TARJATERTTU,
REMES KARI,
RAJAMÄKI ALLAN,
PULKKI KARI
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.8522478.x
Subject(s) - oncostatin m , multiple myeloma , medicine , oncology , interleukin 6 , cytokine
The serum concentration of oncostatin M (OSM) was measured in 40 multiple myeloma patients at diagnosis. Serum OSM level exceeded the sensitivity limit of the ELISA assay in eight (20%) of these patients (OSM + patients). The serum levels of IL‐6, another member of the gp130 cytokine family, and C‐reactive protein (CRP) as a surrogate of IL‐6 were significantly higher in OSM + patients. There was a trend towards higher serum β2M concentration in OSM + patients, whereas there was no difference in the serum sIL‐6R level or clinical data (age, gender, myeloma protein or stage) between the two groups. Two human myeloma cell lines secreted OSM and IL‐6, but not IL‐11 or leukaemia inhibitory factor (LIF), which suggests an important role for OSM and IL‐6 in supporting growth of myeloma cells.